NCT06683469

Brief Summary

This study uses Neutrophil-to-Lymphocyte Ratio to Predict Outcomes of Patients with Aneurysmal Subarachnoid Hemorrhage which will be beneficial in taking early decisions for surgery , patient counselling etc

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 10, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 13, 2023

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

November 8, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 12, 2024

Completed
Last Updated

November 12, 2024

Status Verified

November 1, 2024

Enrollment Period

10 months

First QC Date

November 8, 2024

Last Update Submit

November 8, 2024

Conditions

SAH (Subarachnoid Hemorrhage)

Outcome Measures

Primary Outcomes (1)

  • mRS score

    3 months

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients \> 18 years of age, of either genders, ethnicity and location who presented to the emergency department within 72 hours of the onset of symptoms who underwent surgical or interventional treatment for SAH caused by a ruptured intracranial aneurysm

You may qualify if:

  • Patients \> 18 years of age, of either genders, ethnicity and location who presented to the emergency department within 72 hours of the onset of symptoms who underwent surgical or interventional treatment for SAH caused by a ruptured intracranial aneurysm

You may not qualify if:

  • excluded patients with traumatic SAH, history of infection or stroke within eight weeks, underlying cancer, severe kidney or liver disease, history of auto-immune or hematologic disorder lost to follow-up within three months and individuals declining informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tribhuvan University Teaching Hospital

Kathmandu, 44600, Nepal

Location

Related Publications (1)

  • Guo Y, Liu J, Zeng H, Cai L, Wang T, Wu X, Yu K, Zheng Y, Chen H, Peng Y, Yu X, Yan F, Cao S, Chen G. Neutrophil to lymphocyte ratio predicting poor outcome after aneurysmal subarachnoid hemorrhage: A retrospective study and updated meta-analysis. Front Immunol. 2022 Aug 9;13:962760. doi: 10.3389/fimmu.2022.962760. eCollection 2022.

    PMID: 36016932RESULT

MeSH Terms

Conditions

Subarachnoid Hemorrhage

Condition Hierarchy (Ancestors)

Intracranial HemorrhagesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

November 8, 2024

First Posted

November 12, 2024

Study Start

June 10, 2022

Primary Completion

April 10, 2023

Study Completion

July 13, 2023

Last Updated

November 12, 2024

Record last verified: 2024-11

Locations

NE(1)